Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Group 1 - Centessa Pharmaceuticals plc announced an upsized underwritten public offering of 15,254,237 American Depositary Shares (ADSs) at a price of $14.75 per ADS, expecting gross proceeds of approximately$225 million before expenses [1] - The offering is expected to close on or about September 16, 2024, subject to customary closing conditions, and underwriters have a 30-day option to purchase an additional 2,288,135 ADSs [1] - The ADSs are being offered under a registration statement filed with the SEC on September 11, 2024, which became effective upon filing [3] Group 2 - Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the offering [2] - Centessa Pharmaceuticals focuses on discovering and developing transformational medicines, with advanced programs in hemophilia, narcolepsy, and immuno-oncology [5]